What C4X does
To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.
It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.
This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.
Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.
It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).
It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.
Below is the company’s drug pipeline
What the boss says: Clive Dix
As momentum continues to build across our key programmes, we remain confident in our business strategy with partner discussions to date confirming commercial interest for our NRF-2 programme.
“This follows our already out-licensed Orexin-1 programme which is progressing to clinical studies with Indivior.
“Now in 2020, we will continue to advance the next wave of potential out-licensing candidates and to drive forward partnering deals.”
- Clinical trial for the Orexin-1 programme with Indivior
- A partner for the NRF-2 activator programme with the company seeing commercial interest
- Partners for other projects under development